Thomas Ratliff, MD
Hematology & Oncology · Germantown, TNNPI 1639170665
Payments from drug & device makers
Across 110 payments — averaging $96.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Beigene USA, Inc.$2K
- GSK$2K
- Daiichi Sankyo Inc.$723
- Beigene, Ltd.$417
- Coherus Oncology, Inc.$313
- plus $2K from 29 others
What the payments were for
- Consulting fees$7,40769%
- Food & beverage$3,02828%
- Education$2272%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 5 | $3,378 |
| Beigene USA, Inc. | 4 | $1,723 |
| GSK | 5 | $1,713 |
| Daiichi Sankyo Inc. | 4 | $723 |
| Beigene, Ltd. | 1 | $417 |
| Coherus Oncology, Inc. | 17 | $313 |
| Gilead | 11 | $267 |
| E.r. Squibb & Sons, L.L.C. | 4 | $165 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $151 |
| Beone Medicines USA, Inc. | 4 | $147 |
| Pharmacosmos Therapeutics Inc. | 1 | $125 |
| Mirati Therapeutics, Inc. | 1 | $125 |
| Regeneron Healthcare Solutions, Inc. | 1 | $122 |
| Pfizer | 7 | $116 |
| Amgen | 3 | $109 |
| Adaptive Biotechnologies Corporation | 1 | $106 |
| CTI Biopharma Corp. | 1 | $101 |
| AbbVie | 5 | $98 |
| Novartis | 4 | $96 |
| Astellas Pharma US Inc | 2 | $91 |
| Sanofi | 1 | $89 |
| Johnson & Johnson | 4 | $68 |
| Lilly USA, LLC | 4 | $68 |
| Kyowa Kirin, Inc. | 2 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $43 |
| Caris MPI, Inc. | 2 | $42 |
| ADC Therapeutics America, Inc. | 2 | $42 |
| Bristol Myers Squibb | 1 | $31 |
| Legend Biotech USA Inc. | 1 | $30 |
| Karyopharm Therapeutics Inc. | 1 | $24 |
| Sobi, Inc | 1 | $21 |
| AVEO Pharmaceuticals, Inc. | 1 | $20 |
| Eisai Inc. | 1 | $18 |
| Merck | 1 | $16 |
| Seagen Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,662 in reported general payments places this provider in the 45th percentile of 251 hematology & oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 66 | $1,137,488 |
| JakafiRuxolitinib Phosphate | 44 | $731,911 |
| IbrancePalbociclib | 30 | $461,312 |
| StivargaRegorafenib | 20 | $343,226 |
| FruzaqlaFruquintinib | 13 | $324,620 |
| XtandiEnzalutamide | 23 | $292,560 |
| Lenalidomide | 15 | $226,428 |
| EliquisApixaban | 178 | $185,385 |
| BrukinsaZanubrutinib | 15 | $178,385 |
| CalquenceAcalabrutinib Maleate | 11 | $168,777 |
| LonsurfTrifluridine/Tipiracil Hcl | 12 | $157,649 |
| XareltoRivaroxaban | 103 | $106,482 |
| Imatinib Mesylate | 36 | $77,104 |
| BenlystaBelimumab | 14 | $63,226 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 12 | $46,819 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $31 | $1,137,48866 claims |
| PfizerIbrance, Eliquis, Octagam | $116 | $687,929220 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Fruzaqla | $43 | $324,62013 claims |
| Astellas Pharma US IncXtandi | $91 | $292,56023 claims |
| Beigene USA, Inc.Brukinsa | $1,723 | $178,38515 claims |
| AstraZenecaCalquence | $3,378 | $168,77711 claims |
| Johnson & JohnsonXarelto | $68 | $106,482103 claims |
| GileadGenvoya, Biktarvy | $267 | $89,85823 claims |
| AbbVieCreon, Linzess | $98 | $64,88051 claims |
| GSKBenlysta | $1,713 | $63,22614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 251 hematology & oncology providers in Tennessee.
Other hematology & oncology in Germantown
- David PortnoyGermantown$5.8M
- Bradley SomerGermantown$4.2M
- Jason PorterGermantown$1.8M
- Axel GrotheyGermantown$1M
- Saradasri WellikoffGermantown$260K
- Erika HamiltonNashville$45.4M
- Ian FlinnNashville$41.2M
- Johanna BendellNashville$28.5M
- Jesus BerdejaNashville$22.2M
- Meredith McKeanNashville$16M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.